drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cell)
drug_description
Autologous T cells engineered to express a CD19-directed chimeric antigen receptor (CAR) with CD3ζ and costimulatory signaling; metabolically armed to enhance CAR-T metabolic fitness, expansion, and persistence. Given as a single infusion to target CD19+ B-ALL cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered with a CD19‑directed CAR (CD3ζ signaling plus costimulatory domains) bind CD19 on malignant B cells, triggering T‑cell activation and perforin/granzyme‑mediated cytotoxicity and cytokine release to eliminate CD19+ cells. The cells are metabolically armed to enhance metabolic fitness, expansion, and persistence in vivo, improving antitumor activity.
drug_name
Meta10-19 (metabolically armed CD19 CAR-T cells)
nct_id_drug_ref
NCT05747157